Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00965419 · ClinicalTrials.gov registry record · Phase 2
A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 267
- Enrollment target
NCT00965419: Clinical Trial Phase 2 study, sponsored by Eli Lilly and Company.
NCT00965419 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 267 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (101% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00965419, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 267 participants
- Enrollment target
Study Summary
The primary purpose of the study is to assess long-term safety and tolerability of Edivoxetine in pediatric participants with attention deficit hyperactive disorder (ADHD).
Primary Outcome
Percentage of Participants experienced at least one SAE during the study. A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.
Interventions
- DRUG Edivoxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 267 participants |
| Start Date | 2009-09 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
Why NCT00965419 stopped before completion
NCT00965419 is an interventional study that assigns participants to a tested intervention. The registered 267 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (101% higher).
The record links to 0 conditions, and to 1 intervention - of which Edivoxetine is the first listed.
NCT00965419 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00965419 about?
NCT00965419 is a clinical study titled "A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder". The primary purpose of the study is to assess long-term safety and tolerability of Edivoxetine in pediatric participants with attention deficit hyperactive disorder (ADHD).
What is the current status of trial NCT00965419?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 267 participants. The study started on 2009-09. Estimated completion is 2015-07.
What interventions are being tested in trial NCT00965419?
The interventions under investigation include: Edivoxetine (DRUG).
Who is sponsoring clinical trial NCT00965419?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00965419's enrollment target sits among peer trials
267 209th of 2000 higher than 1,792 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04997109 · 267 participants · NA
Telemedicine in Early Childhood Constraint Therapy in Cerebral Palsy
- NCT05355701 · 267 participants · Phase 1
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
- NCT06203509 · 267 participants · NA
Improving Care Transitions for Medicaid Insured Individuals With Co-occurring Serious Mental Illness
- NCT05000632 · 268 participants · NA
Smoke Free SafeCare: Establishing a Smoke Free Home in CPS-involved Families
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia